Scientists test which dose fights thyroid cancer best

NCT ID NCT01496313

Summary

This study aimed to find the better dose of the drug vandetanib for people with advanced medullary thyroid cancer that was growing or causing symptoms. It involved 81 patients who were randomly assigned to receive either a 150mg or 300mg daily dose. The main goal was to compare how well the cancer responded to each dose and to understand the side effects.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Investigational Site Number : 1901

    Prague, 15006, Czechia

  • Investigational Site Number : 1903

    Olomouc, 77900, Czechia

  • Investigational Site Number : 5703

    Gliwice, 44-101, Poland

  • Investigational Site Number : 5704

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • Research Site

    Houston, Texas, United States

  • Research Site

    Olomouc, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Bangalore Karnataka, India

  • Research Site

    Vellore, India

  • Research Site

    Beersheba, Israel

  • Research Site

    Haifa, Israel

  • Research Site

    Jerusalem, Israel

  • Research Site

    Petah Tikva, Israel

  • Research Site

    Catania, Italy

  • Research Site

    Milan, Italy

  • Research Site

    Palermo, Italy

  • Research Site

    Pisa, Italy

  • Research Site

    Roma, Italy

  • Research Site

    Siena, Italy

  • Research Site

    Torino, Italy

  • Research Site

    Groningen, Netherlands

  • Research Site

    Leiden, Netherlands

  • Research Site

    Gliwice, Poland

  • Research Site

    Warsaw, Poland

  • Research Site

    Zgierz, Poland

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Cardiff, United Kingdom

  • Research Site

    Greater London, United Kingdom

  • Research Site

    London, United Kingdom

  • Research Site

    Tyne & Wear, United Kingdom

Conditions

Explore the condition pages connected to this study.